Optimization of the criteria for cord blood unit selection for transplantation in recipients of the different age groups: current view and prospects in Ukraine

Home/2020, Vol. 8, No. 2/Optimization of the criteria for cord blood unit selection for transplantation in recipients of the different age groups: current view and prospects in Ukraine

Cell and Organ Transplantology. 2020; 8(2):108-120.
DOI: 10.22494/cot.v8i2.115

Optimization of the criteria for cord blood unit selection for transplantation in recipients of the different age groups: current view and prospects in Ukraine

Nemtinov P.1, Ustymenko A.2,3, Lobyntseva G.1, Panchenko L.1, Shupyk O.1, Sokolov M.1, Salyutin R.1, Palіanytsia S.1

  • 1Coordination Center for Transplantation of OrgansTissues and Cells of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • 2State Institute of Genetic and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • 3D. F. Chebotarev State Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine


Umbilical cord blood has been widely used to treat both malignant and non-malignant hematological diseases for over 30 years. During this time, more than 40 000 successful hematopoietic stem cells (HSCs) transplantations of umbilical cord blood have been performed. However, today in Ukraine there is no public umbilical cord blood bank established for unrelated HSCs transplantation to patients with oncohematological diseases (both children and adults). In this regard, the HSCs units must be purchased abroad or the patients are sent to foreign clinics for high-cost treatment.
The establishment of a public umbilical cord blood bank in Ukraine would help in a short time to meet the needs of patients with oncohematological diseases for donor of HSCs for unrelated transplantation and save significant funds for the treatment of patients abroad. According to the experience of the world’s leading oncohematological centers, when it is impossible to find either a related or haploidentical donor or unrelated transplant in all available registries, the search continues in the registers of public cord blood banks and an umbilical cord blood unit that matches the criteria is usually found. The optimal choice of umbilical cord blood unit is crucial to maximize the likelihood of successful transplant engraftment and recipient survival after the transplantation, so the criteria for cord blood unit selection for unrelated transplantation are a bit broader than those used when matching donor-recipient pairs.
The review presents the main criteria for cord blood unit selection according to the assessment of its quality, cell dose, HLA matching for unrelated transplantation to recipients of different age groups in accordance with international guidelines developed by the National Marrow Donor Program (NMDP), Center for International Blood and Marrow Transplant Research (CIBMTR), in collaboration with the NMDP Council Advisory Group, as well as in accordance with the American Society for Transplantation and Cellular Therapy (ASTCT) and the 7th Edition of the NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration.

Key words: cord blood; unrelated transplantation of hematopoietic stem cells; oncohematological diseases

Full Text PDF (eng) Full Text PDF (ua)

1. Available: https://wmda.info/cord-blood/basics-cord-blood/ 
2. Available: http://www.ukrstat.gov.ua/
3. Available: https://ubmdr.org/
4. Algwaiz G, et al. Guideline: Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020; 26:2181-2189. DOI:10.1016/j.bbmt.2020.07.021.
PMid:32717432 PMCid:PMC7380217
5. Available: https://www.belstat.gov.by/
6. Cairo MS, Kindwall-Keller TL. Indications for Utilization of Stored Umbilical Cord Blood. 2018. Available online: https://www.cb-association.org/indications-for-utilization-of-stored-umbilical-cord-blood.
7. Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol. 2009; 147(2):246-261.
PMid:19796274 PMCid:PMC2782564
8. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLAidentical sibling. N Engl J Med. 2000; 342(25):1846-1854.
9. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014; 371(4):339-348.
PMid:25054717 PMCid:PMC5965695
10. Brown KS, Rao MS, Brown HL. The Future State of Newborn Stem Cell Banking. J Clin Med. 2019; 8(1):117. DOI:10.3390/jcm8010117.
PMid:30669334 PMCid:PMC6352006
11. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: Public or private? Bone Marrow Transpl. 2015; 50:1271-1278.
12. Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl Med. 2018; 7:643-650.
PMid:29777574 PMCid:PMC6127225
13. Kurtzberg J. A History of Cord Blood Banking and Transplantation. Stem Cells Transl Med. 2017; 6:1309-1311.
PMid:28456005 PMCid:PMC5442723
14. Ballen K. Update on umbilical cord blood transplantation. F1000Research. 2017; 6: 1556.
PMid:28928957 PMCid:PMC5580430
15. Jöris M, et al. Worldwide survey on key indicators for public cord blood banking technologies: By the World Marrow Donor Association Cord Blood Working Group Stem Cells. Transl Med. 2021; 10(2):222-229. DOI:10.1002/sctm.20-0246.
PMid:33047891 PMCid:PMC7848355
16. Available: https://cryobank.ua/
17. Baumgartner LS; Moore E; Shook D, Messina S, Day MC, Green J Nandy, et al. Safety of Autologous Umbilical Cord Blood Therapy for Acquired Sensorineural Hearing Loss in Children. J Audiol Otol. 2018; 22:209-222.
PMid:30126263 PMCid:PMC6233943
18. Dawson G, Sun J, Davlantis KS, Murias M, Franz L, Troy J, et al. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl. Med. 2017; 6:1332-1339.
PMid:28378499 PMCid:PMC5442708
19. Sun JM, Song AW, Case LE, Mikati MA, Gustafson KE, Simmons R, et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Transl Med. 2017; 6:2071-2078.
PMid:29080265 PMCid:PMC5702515
20. Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl Med. 2018; 7:333-341.
PMid:29405603 PMCid:PMC5866927
21. Sun J, Allison J, McLaughlin C, Sledge L, Waters-Pick B, Wease S, et al. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion. 2010; 50:1980-1987.
PMid:20546200 PMCid:PMC3816574
22. Lengel D, et al. Stem Cell Therapy for Pediatric Traumatic Brain Injury. Front Neurol. 2020; 11:601286. DOI:10.3389/fneur.2020.601286.
PMid:33343501 PMCid:PMC7738475
23. Laskowitz DT, Bennett ER, Durham RJ, Volpi JJ, Wiese JR, Frankel M, et al. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase 1 Safety Study. Stem Cells Transl Med. 2018; 7:521-529.
PMid:29752869 PMCid:PMC6052613
24. Ruggeri A. Optimizing cord blood selection. Hematology. 2019; 1:522-531.
PMid:31808851 PMCid:PMC6913431
25. Skiles ML, Brown KS, TatzW, Swingle K, Brown HL. Quantitative analysis of composite umbilical cord tissue health using a standardized explant approach and an assay of metabolic activity. Cytotherapy. 2018; 20:564-575.
26. Available: https://csict.com.ua/rnd/about/research/
27. Available: https://moz.gov.ua/article/news/maksim-stepanov-pidpisav-memorandum-z-ukrainskim-reestrom-donoriv-kistkovogo-mozku-ta-idonor.
28. Alyansky AL, Makarenko OA, Ivanova NE, et al. Razvitie registra nerodstvennykh donorov kostnogo mozga v Rossiyskoy Federatsii: opyt NII detskoy onkologii, gematologii i transplantologii im. R. M. Gorbachevoy [Development of the register of unrelated bone marrow donors in the Russian Federation: the experience of the Research Institute of Pediatric Oncology, Hematology and Transplantology named after R. M. Gorbacheva]. Rossiyskiy zhurnal detskoy gematologii i onkologii – Russian Journal of Pediatric Hematology and Oncology. 2016; 3(2):68-74. DOI: 10.17650/2311-1267-2016-3-2-68-74. [In Russian] https://doi.org/10.17650/2311-1267-2016-3-2-68-74
29. Hamaganova EG, Kuzminova EP, Abdrakhimova AR, et al. Geneticheskie distantsii po HLA-genam mezhdu donorami gemopoeticheskikh stvolovykh kletok registra FGBU «NMITs gematologii» Minzdrava Rossii i drugimi rossiyskimi i mirovymi populyatsiyami [Genetic distances by HLA genes between donors of hematopoietic stem cells of the register of the Federal State Budgetary Institution “National Medical Research Center of Hematology” of the Ministry of Health of Russia and other Russian and world populations]. Transfuziologiya – Transfusiology. 2018; 19(1):13-26. [In Russian]
30. Müller CR, Ehninger G, Goldmann SF. Gene and haplotype frequencies for the loci HLA-A, HLA-B, and HLA-DR based on over 13,000 German blood donors. Hum Immunol. 2003; 64(1):137-51. DOI: 10.1016/S0198-8859(02)00706-1.
31. Center for International Blood and Marrow Transplant Research / Transplant Activity Report Covering 2013-2017 / Table 14. Number of HCTs performed in the United States and reported to CIBMTR – donor type and cell source by year 2013-2017 https://bloodstemcell.hrsa.gov/sites/default/files/bloodstemcell/data/transplant-activity/transplants-year-donor-type-cell-source.pdf
32. Available: https://www.who.int/countries/usa/ru/
33. Oksenoit GK, Nikitina SYu, Ageeva LI, et al. Zdravookhranenie v Rossii 2017 [Healthcare in Russia 2017] Stat. sb./Rosstat – stat. coll./Rosstat collection. Мoscow, 2017. 170 p. [In Russian]
34. Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, et al. What are a patient’s current chances of finding a matched unrelated donor? Twenty years’ central search experience in a small country. Bone Marrow Transplant. 2012; 47(2):172-80. DOI: 10.1038/bmt.2011.67.
35. Mendeleeva LP, Savchenko VG, Parovichnikova EN, et al. Analiz transplantatsionnoy aktivnosti v RF za 2018 god (otchet mezhregional’nogo registra) [Analysis of transplantation activity in the Russian Federation in 2018 (the interregional register report)]. Gematologiya i transfuziologiya – Hematology and Transfusiology. 2020; 65(1):180. [In Russian]
36. Passweg JR, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018; 53(9):1139-48. DOI:10.1038/s41409-018-0153-1.
PMid:29540849 PMCid:PMC6128821
37. Available: https://showdata.gks.ru/report/278928/
38. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016; 51(6):778-85.
PMid:26901703 PMCid:PMC4889523
39. Yamamoto H. Single cord blood transplantation in Japan; expanding the possibilities of CBT. International Journal of Hematology. 2019; 110:39-49. Available: DOI:10.1007/s12185-019-02672-4.
40. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012; 367:2305-2315.
PMid:23234514 PMCid:PMC3805360
41. Wagner JEJr, Brunstein CG, Boitano AE, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016; 18:144-155.
PMid:26669897 PMCid:PMC4881386
42. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014; 345:1509-1512.
PMid:25237102 PMCid:PMC4372335
43. Stiff PJ, Montesinos P, Peled T, et al. Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biol Blood Marrow Transplant. 2018; 24:1463-1470.
PMid:29477778 PMCid:PMC6045964
44. Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Rev Hematol. 2016; 9(3):297-314.
45. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010; 16(2):232-236.
PMid:20081862 PMCid:PMC2819359
46. Vasilyeva VA, Kuzmina LA, Parovichnikova EN, Drokov MYu, Dmitrova AA, Starikova OS, et al. Vypolnenie transplantatsiy allogennykh gemopoeticheskikh stvolovykh kletok ot nerodstvennykh donorov iz Rossiyskogo i zarubezhnogo registrov v odnom transplantatsionnom tsentre [The allogeneic hematopoietic stem cells transplantation from unrelated donors from the Russian and foreign registries in the same transplant center]. Gematologiya i transfuziologiya – Hematology and transfusiology. 2020; 65(3):299-311. DOI:10.35754/0234-5730-2020-65-3-299-311. [In Russian] https://doi.org/10.35754/0234-5730-2020-65-3-299-311
47. Furst D, Muller C, Vucinic V, et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood. 2013; 122(18):3220-9. DOI:10.1182/blood-2013-02-482547.
48. Morishima Y, Kawase T, Malkki M, et al. Signifi cance of ethnicity in the risk of acute graft-versus-Host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(8):1197-203. DOI: 10.1016/j.bbmt.2013.05.020.
PMid:23747601 PMCid:PMC3972059
49. Politikos I, et al. Guidelines for Cord Blood Unit Selection. Practice quidelines. TCT. 2020; 26(12):2190-2196. DOI:10.1016/j.bbmt.2020.07.030.
50. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013; 122(4):491-498.
PMid:23673863 PMCid:PMC3952633
51. Pasquini MC, et al. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation 2019; 25:2322-2329. DOI:10.1016/j.bbmt.2019.05.002.
52. Dehn J, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019; 134(12):924-934; DOI:10.1182/blood.2019001212.
PMid:31292117 PMCid:PMC6753623
53. Hough R, Danby R, Russell N, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016; 172:360-370.
54. Ruggeri A, Paviglianiti A, Gluckman E, Rocha V. Impact of HLA in cord blood transplantation outcomes. HLA. 2016; 87:413-421.
55. Barker JN, Kurtzberg J, Ballen K, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017; 23:882-896.
PMid:28279825 PMCid:PMC5543989
56. Yanada M, Konuma T, Kuwatsuka Y, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone MarrowTransplant. 2019; 54:1789-1798.
57. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatmentrelated mortality and survival. Blood. 2002; 100:1611-1618.
58. Terakura S, Azuma E, Murata M, et al. Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol Blood Marrow Transplant. 2007; 13:822-830.
59. Konuma T, Kato S, Oiwa-Monna M, et al. Cryopreserved CD34(+) cell dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017; 23:1142-1150.
60. Purtill D, Smith K, Devlin S, et al. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood. 2014; 124:2905-2912.
PMid:25185264 PMCid:PMC4224191
61. Lemarie C, Esterni B, Calmels B, et al. CD34(+) progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation. Bone Marrow Transplant. 2007; 39:453-460.
62. Wagner Jr JE, Eapen M, Carter S, et al. One-unit versus two-unit cordblood transplantation for hematologic cancers. N Engl J Med. 2014; 371:1685-1694.
PMid:25354103 PMCid:PMC4257059
63. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998; 339:1565-1577.
64. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. 2008; 112:4318-4327.
PMid:18723429 PMCid:PMC2581998
65. Cohen YC, Scaradavou A, Stevens CE, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011; 46:70-76.
PMid:20436518 PMCid:PMC3366187
66. Michel G, Galambrun C, Sirvent A, et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood. 2016; 127:3450-3457.
67. Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014; 123:133-140.
PMid:24141369 PMCid:PMC3879902
68. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011; 12:1214-1221.
69. Atsuta Y, Kanda J, Takanashi M, et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 2013; 98:814-822.
PMid:23349300 PMCid:PMC3640130
70. Yokoyama H, Morishima Y, Fuji S, et al. Impact of HLA allele mismatch at HLA-A, -B, -C, and -DRB1 in single cord blood transplantation. Biol Blood Marrow Transplant. 2020; 26:519-528.
71. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010; 115:1843-1849.
PMid:20029048 PMCid:PMC5003507
72. Ballen KK, Logan BR, Laughlin MJ, et al. Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2015; 21:688-695.
PMid:25543094 PMCid:PMC4359657
73. Gluckman E, Rocha V, Ionescu I, et al. Results of unrelated cord blood transplant in Fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant. 2007; 13:1073-1082.
74. Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018; 132:750-754.
75. Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2011; 17:78-85.
76. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006; 18:565-570.
77. Fernandes JF, Rocha V, Labopin M, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood. Blood. 2012; 119:2949-2955.
78. Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013; 121:3981-3987.
PMid:23493783 PMCid:PMC3836041
79. Nakasone H, Tabuchi K, Uchida N, et al. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells. Br J Haematol. 2019; 185:166-169.
80. Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2010; 16:86-94.
81. Page KM, Zhang L, Mendizabal A, et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol BloodMarrow Transplant. 2011; 17:1362-1374.
82. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001; 344:1815-1822.
83. Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012; 40: 342-355.
84. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367:1487-1496.
PMid:23075175 PMCid:PMC3816375
85. Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015; 21:1299-1307.
86. Mielcarek M, Furlong T, O’Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016; 127:1502-1508.
PMid:26764356 PMCid:PMC4797026
87. Anand S, Thomas S, Hyslop T, et al. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant. 2017; 23:1151-1157.
PMid:28392378 PMCid:PMC5846194
88. Horwitz ME, Wease S, Blackwell B, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019; 37(5):367-374. DOI:10.1200/JCO.18.00053.
PMid:30523748 PMCid:PMC6368416
89. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014; 124:3121-3128.
PMid:24911148 PMCid:PMC4071379
90. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005; 105:1343-1347.
91. Barker JN, Fei M, Karanes C, et al. Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. Br J Haematol. 2015; 168:405-412.
PMid:25272241 PMCid:PMC5557396
92. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009; 114:4293-4299.
PMid:19706886 PMCid:PMC2774557
93. Balligand L, Galambrun C, Sirvent A, et al. Single-unit versus double-unit umbilical cord blood transplantation in children and young adults with residual leukemic disease. Biol Blood Marrow Transplant. 2019; 25:734-742.
94. Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2011; 117:3277-3285.
PMid:21149633 PMCid:PMC3069669
95. Purtill D, Stevens CE, Lubin M, et al. Association between nondominant unit total nucleated cell dose and engraftment in myeloablative doubleunit cord blood transplantation. Biol Blood Marrow Transplant. 2015; 21:1981-1984.
PMid:26211983 PMCid:PMC4604060
96. Bejanyan N, Rogosheske J, DeFor T, et al. Higher dose of mycophenolate mofetil reduces acute graft-versus-host disease in reduced-intensity conditioning double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2015; 21:926-933.
PMid:25655791 PMCid:PMC4768800
97. Brunstein CG, Petersdorf EW, DeFor TE, et al. Impact of allele-level HLA mismatch on outcomes in recipients of double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2016; 22:487-492.
PMid:26431630 PMCid:PMC4753126
98. Tozatto-Maio K, Giannotti F, Labopin M, et al. Cord blood unit dominance analysis and effect of the winning unit on outcomes after double-unit umbilical cord blood transplantation in adults with acute leukemia: a retrospective study on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018; 24:1657-1663.
99. Haspel RL, Kao G, Yeap BY, et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008; 41:523-529.
PMid:18037942 PMCid:PMC2947748
100. Gupta AO, Wagner JE. Umbilical Cord Blood Transplants: Current Status and Evolving Therapies. Front Pediatr. 2020; 8:570282. DOI:10.3389/fped.2020.570282.
PMid:33123504 PMCid:PMC7567024
101. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011; 118:6438-45. DOI:10.1182/blood-2011-08-372508.
PMid:21976674 PMCid:PMC3236125
102. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018; 24:359-65. DOI:10.1016/j.bbmt.2017.10.040.
PMid:29128555 PMCid:PMC6574086
103. Ephraim J. Fuchs, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021; 137(3):420-428.
104. Duihong Li, Xiaofan Li, Lianming Liao, Nainong Li. Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies -A meta-analysis and systematic review. Am J Blood Res. 2020;10(1):1-10.
PMid:32206440 PMCid:PMC7076284
105. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010; 75(4):291-455.
PMid:20356336 PMCid:PMC2848993
106. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, ParhamP, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2015; 43:D423-D431.
PMid:25414341 PMCid:PMC4383959
107. European Federation for Immunogenetics. Standards for Histocompatibility & Immunogenetics Testing. 2019.Version 7. Available at: https://www.efi-web.org/news/version-7-ofthe-standards-for-histocompatibilityimmunogentics-testing.html.
108. Nunes E, Heslop H, Fernandez-Vina M, et al. Definitions of histocompatibility typing terms. Blood. 2011; 118(23):e180-e183.
109. Hou L, Vierra-Green C, Lazaro A, et al. Limited HLA sequence variation outside of antigen recognition domain exons of 360 10 of 10 matched unrelated hematopoietic stem cell transplant donor-recipient pairs. HLA. 2017; 89(1):39-46.
PMid:27976839 PMCid:PMC5425813
110. Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLAspecific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010; 115(13):2704-2708.
PMid:20089963 PMCid:PMC2852369
111. Ciurea SO, Thall PF, Wang X, et al. Donorspecific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011; 118(22): 5957-5964.
PMid:21967975 PMCid:PMC3761379
112. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011; 117:2332-2339.
PMid:21149636 PMCid:PMC3062405
113. Yanada M, Konuma T, Kuwatsuka Y, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplant. 2019; 54:1789-1798.
114. Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004; 32:397-407.
115. Kanda J., Hayashi H., Ruggeri A., et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia. 2020. 34. P. 128-137.
116. Politikos I, Mazis CM, Naputo KA, et al. Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units. Bone Marrow Transplant. 2020; DOI:10.1038/s41409-020-01042-7.
117. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007; 369:1947-1954.
118. Scaradavou A, et al. Guidelines for Cord Blood Unit Thaw and Infusion / Biol Blood Marrow Transplant. 2020; 26:1780-1783.
119. Sanz J, Jaramillo FJ, Planelles D, et al. Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2014; 20:106-110.
120. Ponce DM, Hilden P, Devlin SM, et al. High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2015; 21:1985-1993.
PMid:26238810 PMCid:PMC4768474
121. Oran B, Cao K, Saliba RM, et al. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015; 100:1361-1370.
PMid:26250579 PMCid:PMC4591769
122. Delaney M, Cutler CS, Haspel RL, et al. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009; 49:995-1002.
PMid:19159415 PMCid:PMC2763583
123. Brunstein C, Zhang MJ, Barker J, et al. The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. Haematologica. 2017; 102:941-947.
PMid:28126967 PMCid:PMC5477613
124. Ballen K, Logan BR, Chitphakdithai P, et al. Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: a study of 2456 umbilical cord blood recipients. Biol Blood Marrow Transplant. 2020; 26:745-757.
PMid:31756539 PMCid:PMC7198366
125. Eapen M, Wang T, Veys PA, et al. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017; 4:e325-e333.
126. Mallhi KK, Smith AR, DeFor TE, Lund TC, Orchard PJ, Miller WP. Allele-level HLA matching impacts key outcomes following umbilical cord blood transplantation for inherited metabolic disorders. Biol Blood Marrow Transplant. 2017; 23:119-125.
127. Konuma T, Kato S, Ishii H, et al. HLA-DRB1 mismatch is associated with a decreased relapse in adult acute myeloid leukemia after single-unit myeloablative cord blood transplantation. Ann Hematol. 2015; 94:1233-1235.
128. Brunstein CG, Cutler CS, DeFor TE, et al. Matching at human leukocyte antigen-C improved the outcomes after double umbilical cord blood transplantation for recipients of two to four of six human leukocyte antigen-matched grafts. Biol Blood Marrow Transplant. 2017; 23:126-133.
PMid:27989929 PMCid:PMC5510875
129. Yabe T, Azuma F, Kashiwase K, et al. HLA-DPB1 mismatch induces a graftversus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation. Leukemia. 2018; 32:168-175.
130. Matsuno N, Wake A, Uchida N, et al. Impact of HLA disparity in the graftversus-host direction on engraftment in adult patients receiving reducedintensity cord blood transplantation. Blood. 2009; 114:1689-1695.
131. Cunha R, Loiseau P, Ruggeri A, et al. Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplant. 2014; 49:24-29.
132. Kanda J, Atsuta Y, Wake A, et al. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2013; 19:247-254.
133. Rocha V, Spellman S, Zhang MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012; 18:1890-1896.
PMid:22814031 PMCid:PMC3826155
134. Van der Zanden HG, Van Rood JJ, Oudshoorn M, et al. Noninherited maternal antigens identify acceptable HLA mismatches: benefit to patients and cost-effectiveness for cord blood banks. Biol Blood Marrow Transplant. 2014; 20:1791-1795.
135. van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci U S A. 2012; 109:2509-2514.
PMid:22232664 PMCid:PMC3289309
136. van Rood JJ, Stevens CE, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci U S A. 2009; 106:19952-19957.
PMid:19901324 PMCid:PMC2775036
137. Switzer GE, Bruce JG, Myaskovsky L, et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood. 2013; 121(8):1469-1476.
PMid:23258921 PMCid:PMC3578960
138. Paunic’ V, Gragert L, Schneider J, Mu¨ ller C, Maiers M. Charting improvements in US registry HLA typing ambiguity using a typing resolution score. Hum Immunol. 2016; 77(7):542-549.
139. Gaudieri S, Leelayuwat C, Tay GK, Townend DC, Dawkins RL. The major histocompatibility complex (MHC) contains conserved polymorphic genomic sequences that are shuffled by recombination to form ethnic-specific haplotypes. J Mol Evol. 1997; 45(1):17-23.
140. Scaradavou A, Smith KM, Hawke R, et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant. 2010; 16:500-508.
PMid:19932758 PMCid:PMC4606455
141. Barker JN, Scaradavou A. Response: the controversy of red blood cellreplete cord blood units. Blood. 2011; 118(2):480.
142. Jaing TH, Chen SH, Wen YC, Chang TY, Yang YC, Tsay PK. Effects of cryopreservation duration on the outcome of single-unit cord blood transplantation. Cell Transplant. 2018; 27:515-519.
PMid:29737201 PMCid:PMC6038043
143. Nikiforow S, Li S, Snow K, et al. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017; 19:272-284.
144. Mitchell R, Wagner JE, Brunstein CG, et al. Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes. Biol Blood Marrow Transplant. 2015; 21:50-54.
PMid:25262882 PMCid:PMC4378826
145. Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010; 116:2839-2846.
146. Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion. 2008; 48:791-793.
147. Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011; 118:6691-6697.
PMid:21940825 PMCid:PMC3976219
148. Yamamoto H, Uchida N, Matsuno N, et al. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. Biol Blood Marrow Transplant. 2014; 20:1634-1640.
149. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011; 17:1704-1708.
PMid:21601639 PMCid:PMC3168972
150. Dahi PB, Barone J, Devlin SM, et al. Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies. Biol Blood Marrow Transplant. 2014; 20:735-739.
PMid:24462980 PMCid:PMC3984623
151. Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53:521-534.
PMid:29335625 PMCid:PMC7232774
152. Gladstone DE, Bettinotti MP. HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. Hematology Am Soc Hematol Educ Program. 2017; 2017:645-650.
PMid:29222316 PMCid:PMC6142580
153. Wada S, Asano-Mori Y, Yamamoto H, et al. No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation. Bone Marrow Transplant. 2019; 54:765-768.
154. Kudek MR, Shanley R, Zantek ND, McKenna DH, Smith AR, Miller WP. Impact of graft-recipient ABO compatibility on outcomes after umbilical cord blood transplant for nonmalignant disease. Biol Blood Marrow Transplant. 2016; 22:2019-2024.
PMid:27496217 PMCid:PMC5067229
155. Konuma T, Kato S, Ooi J, et al. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning. Biol Blood Marrow Transplant. 2014; 20:577-581.
156. Romee R, Weisdorf DJ, Brunstein C, et al. Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation. Bone Marrow Transplant. 2013; 48:1046-1049.
PMid:23419434 PMCid:PMC3740145
157. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009; 113:5628-5634.
PMid:19329778 PMCid:PMC2689057
158. Tanaka J, Morishima Y, Takahashi Y, et al. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J. 2013; 3:e164.
PMid:24292416 PMCid:PMC3880445
159. Tarek N, Gallagher MM, Chou JF, et al. KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation. Bone Marrow Transplant. 2015; 50:150-152.
PMid:25310305 PMCid:PMC4286450
160. Rettman P, Malard F, Legrand N, et al. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes: results of a French multicentric retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) and the Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI). Bone Marrow Transplant. 2016; 51:1499-1503.
161. Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016; 128:297-312.
PMid:27247137 PMCid:PMC4946205
162. Rocha V, Ruggeri A, Spellman S, et al. Killer cell immunoglobulin-like receptor-ligand matching and outcomes after unrelated cord blood transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant. 2016; 22:1284-1289.
PMid:27090957 PMCid:PMC4915071
163. Dehn J, Setterholm M, Buck K, Kempenich J, Gragert L, Madbouly A, et al. HapLogic: A Predictive Human Leukocyte Antigen-Matching Algorithm to Enhance Rapid Identification of the Optimal Unrelated Hematopoietic Stem Cell Sources for Transplantation Biol Blood Marrow Transplant. 2016; 22(11):2038-2046. DOI: 10.1016/j.bbmt.2016.07.022.

Nemtinov P, Ustymenko A, Lobyntseva G, Panchenko L, Shupyk O, Sokolov M, Salyutin R, Palіanytsia S. Optimization of the criteria for cord blood unit selection for transplantation in recipients of the different age groups: current view and prospects in Ukraine. Cell Organ Transpl. 2020; 8(2):108-120. doi:10.22494/cot.v8i2.115

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.